Artimplant Signs Distribution Agreement With BioMedtrix

Artimplant has made their first entry into the veterinary field with a canine knee ligament implant.

The Swedish biomaterial company Artimplant has signed an exclusive U.S. distribution agreement with BioMedtrix for its Artelon CCL, a new biodegradable implant for the reconstruction of canine knee ligaments.

This is Artimplant’s first entry in the veterinary field. Previously, the product was used for anterior cruciate ligament augmentation in humans.

To date, about 30 dogs have received Artelon implants.

“The extent of CCL (cranial cruciate ligament) ruptures in the United States has been estimated to be over 300,000 cases annually,” said Christopher Sidebotham, chief executive officer of BioMedtrix.

“BioMedtrix expects to enter this market in 2009 based on scientific research and the experience of veterinarian leaders in the industry,” Sidebotham said. “With the U.S. documentation in place, our expected clinical cases in the first year will be 10,000 procedures with an aggressive annual growth towards establishing the Artelon CCL procedure as the standard for CCL repair.”

BioMedtrix of Boonton, N.J., will establish clinical sites, train the veterinary community and support the program through prospective studies.

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.